Seven RCTs were included for meta-analysis (n=1,733). No details from the quality assessment were reported. Funnel plots were not used to assess publication bias due to the small number of studies.
Prophylactic use of G-CSF after chemotherapy did not increase overall survival rates significantly in acute myeloid leukemia patients (HR 0.95, 95% CI 0.85 to 1.07). No significant heterogeneity was found.
No significant differences were found between G-CSF type, or by excluding studies with less than 100 patients.